Sign In
Buy BHST
Bioharvest Sciences . Common Stock Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS Surprise | 15.38% |
| Revenue estimate | 8.5M |
| Revenue actual | 8.507M |
| Revenue Surprise | 0.0824% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$0.105 |
| EPS actual | -$0.100 |
| EPS Surprise | 4.76% |
| Revenue estimate | 9.239M |
| Revenue actual | 9.1M |
| Revenue Surprise | -1.50% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.140 |
| Revenue estimate | 9.159M |
| Revenue actual | 9.067M |
| Revenue Surprise | -1.00% |
| Release date | Aug 11, 2025 |
| EPS estimate | -$0.110 |
| EPS actual | -$0.150 |
| EPS Surprise | -36.36% |
| Revenue estimate | 9.061M |
| Revenue actual | 8.515M |
| Revenue Surprise | -6.03% |
Last 4 Quarters for Bioharvest Sciences . Common Stock
Below you can see how BHST performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 11, 2025 |
| Price on release | $8.82 |
| EPS estimate | -$0.110 |
| EPS actual | -$0.150 |
| EPS surprise | -36.36% |
| Date | Price |
|---|---|
| Aug 05, 2025 | $7.50 |
| Aug 06, 2025 | $7.90 |
| Aug 07, 2025 | $8.10 |
| Aug 08, 2025 | $8.76 |
| Aug 11, 2025 | $8.82 |
| Aug 12, 2025 | $9.11 |
| Aug 13, 2025 | $9.49 |
| Aug 14, 2025 | $9.22 |
| Aug 15, 2025 | $9.32 |
| 4 days before | 17.61% |
| 4 days after | 5.70% |
| On release day | 3.28% |
| Change in period | 24.31% |
| Release date | Nov 13, 2025 |
| Price on release | $7.30 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.140 |
| Date | Price |
|---|---|
| Nov 07, 2025 | $7.13 |
| Nov 10, 2025 | $7.31 |
| Nov 11, 2025 | $6.88 |
| Nov 12, 2025 | $7.90 |
| Nov 13, 2025 | $7.30 |
| Nov 14, 2025 | $7.23 |
| Nov 17, 2025 | $6.80 |
| Nov 18, 2025 | $6.79 |
| Nov 19, 2025 | $6.31 |
| 4 days before | 2.38% |
| 4 days after | -13.56% |
| On release day | -0.96% |
| Change in period | -11.50% |
| Release date | Mar 31, 2026 |
| Price on release | $4.34 |
| EPS estimate | -$0.105 |
| EPS actual | -$0.100 |
| EPS surprise | 4.76% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $4.36 |
| Mar 26, 2026 | $4.32 |
| Mar 27, 2026 | $4.32 |
| Mar 30, 2026 | $4.27 |
| Mar 31, 2026 | $4.34 |
| Apr 01, 2026 | $4.31 |
| Apr 02, 2026 | $4.28 |
| Apr 06, 2026 | $4.36 |
| Apr 07, 2026 | $4.31 |
| 4 days before | -0.459% |
| 4 days after | -0.691% |
| On release day | -0.691% |
| Change in period | -1.15% |
| Release date | May 14, 2026 |
| Price on release | $4.16 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS surprise | 15.38% |
| Date | Price |
|---|---|
| May 08, 2026 | $3.97 |
| May 11, 2026 | $3.69 |
| May 12, 2026 | $3.84 |
| May 13, 2026 | $4.01 |
| May 14, 2026 | $4.16 |
| May 15, 2026 | $4.10 |
| May 18, 2026 | $3.96 |
| May 19, 2026 | $3.92 |
| May 20, 2026 | $3.72 |
| 4 days before | 4.79% |
| 4 days after | -10.58% |
| On release day | -1.44% |
| Change in period | -6.30% |
Bioharvest Sciences . Common Stock Earnings Call Transcript Summary of Q1 2026
BioHarvest reported Q1 2026 revenue of $8.5M (up 8% YoY) with gross margin ~59%. Q1 net loss was $2.6M ($0.11/share); adjusted EBITDA loss was $1.2M. Cash and deposits rose to $20.2M vs. $3.4M a year ago. Management reorganized around a two-lens model (CDMO services and D2C products) and executed a leadership transition to optimize both businesses. CDMO highlights: completion of Stage 1 for a rare, high-value fragrance molecule and signing a $1.2M Stage 2 contract (BioHarvest retains 20% ownership of developed compositions), completion of Stage 1 with Saffron Tech and progression to Stage 2, and a pipeline expecting at least 3–4 additional projects this year. Company reiterates CDMO 2026 revenue guidance of $12M–$14M (including intercompany VINIA production) and service-related CDMO revenue of $4M–$6M. Total adjusted EBITDA loss for 2026 is guided to $4M–$5M. D2C highlights (VINIA): >90,000 active users, VINIA Blood Flow Hydration showing rapid adoption and high ratings (avg. 4.7/5), and 2026 D2C revenue guidance of $38M–$42M with adjusted EBITDA profit of $0.5M–$2M. Management expects the new manufacturing facility to begin adding production capacity in the second half of 2027, enabling simultaneous multi-compound production and supporting commercial launches (including fragrance and saffron products) into H2 2027 and beyond. Key strategic priorities: selective focus on higher-margin nutraceutical and fragrance opportunities, improving D2C unit economics (LTV/CAC), scaling VINIA products (new chews and hydration), and continuing business development to convert pipeline opportunities into contracts.
